Stay updated with breaking news from குளோன் மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange News provided by Share this article Share this article SHANGHAI, March 3, 2021 /PRNewswire/ SciClone Pharmaceuticals (Holdings) Limited ( SciClone Pharmaceuticals or SciClone ) was officially listed today on the Main Board of The Stock Exchange of Hong Kong Limited ( Hong Kong Stock Exchange or HKEx ) under stock code: 6600. In the initial offering, the 11,599,000 shares offered for subscription in the Hong Kong Public Offering was oversubscribed by 1,068.05 times. The Offer Price was HK$18.80 per Offer Share, and the Global Offering has raised a total amount of HK$2,039.5 million in net proceeds (after deducting underwriting fees and commissions paid and payable in connection with the global offering and estimated expenses and assuming the Over-allotment Option is not exercised). ....
SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.
Chinese healthcare trio premarket Hong Kong lisitngs globalcapital.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalcapital.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China Y-mAbs Therapeutics, IncDecember 18, 2020 GMT NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a license agreement with SciClone Pharmaceuticals International Ltd (“SciClone”) to be the exclusive co-development and commercialization partner of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma i ....
Y-mAbs Signs License Agreement with SciClone for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in China marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.